Cantor Fitzgerald Forecasts ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will earn $0.24 per share for the year. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share.

A number of other analysts have also commented on the stock. Guggenheim lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Raymond James restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. StockNews.com cut shares of ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 14th. HC Wainwright restated a "buy" rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $25.25.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD traded up $1.27 during midday trading on Thursday, reaching $19.08. The company had a trading volume of 2,483,459 shares, compared to its average volume of 4,689,989. The company has a fifty day simple moving average of $17.26 and a two-hundred day simple moving average of $16.59. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of 24.46 and a beta of 0.37. ACADIA Pharmaceuticals has a 1-year low of $14.15 and a 1-year high of $29.29.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.06. The company had revenue of $250.40 million for the quarter, compared to analysts' expectations of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business's revenue was up 18.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.40) EPS.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. State Street Corp lifted its holdings in shares of ACADIA Pharmaceuticals by 3.0% during the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company's stock worth $91,878,000 after buying an additional 173,084 shares during the last quarter. Fred Alger Management LLC increased its position in ACADIA Pharmaceuticals by 17.8% during the third quarter. Fred Alger Management LLC now owns 3,186,389 shares of the biopharmaceutical company's stock worth $49,007,000 after acquiring an additional 481,950 shares during the period. Millennium Management LLC boosted its holdings in ACADIA Pharmaceuticals by 36.2% in the 2nd quarter. Millennium Management LLC now owns 2,937,714 shares of the biopharmaceutical company's stock valued at $47,738,000 after purchasing an additional 781,070 shares during the period. D. E. Shaw & Co. Inc. grew its position in ACADIA Pharmaceuticals by 11.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,934,926 shares of the biopharmaceutical company's stock worth $47,693,000 after purchasing an additional 292,906 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in ACADIA Pharmaceuticals by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company's stock worth $44,234,000 after purchasing an additional 30,826 shares during the last quarter. Institutional investors own 96.71% of the company's stock.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, CFO Mark C. Schneyer sold 10,259 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the transaction, the chief financial officer now owns 53,302 shares of the company's stock, valued at approximately $896,006.62. This represents a 16.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James Kihara sold 4,073 shares of the business's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the completion of the sale, the insider now owns 19,863 shares of the company's stock, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,661 shares of company stock worth $414,551 over the last ninety days. 28.30% of the stock is currently owned by insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.